BASF Pharma Callanish production approved by Korean FDA

BASF Pharma Callanish, a cGMP-certified production facility in the Western Isles of Scotland has recently received approval from the Korean Food and Drug Administration (KFDA) to sell concentrated omega-3 fatty acids as active pharmaceutical ingredients in Korea.

BASF Pharma Callanish specializes in the production of highly concentrated omega oils for use in pharmaceuticals and high-end dietary supplements.

“We are very pleased about this approval since Korea is an important pharmaceutical market for us,” said Alan Poon, Head of Pharma Ingredients & Services in Asia Pacific. “We expect approvals in other Asian markets to follow, as we broaden our offering of omega-3 concentrates for the pharmaceutical sector even further.”